New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
11:37 EDTLLY, PSTI, NBS, OVSC, LH, ATHX, STEM, CYTX, ACTC, PFE, FLDMGenetics Policy Institute to host a summit
World Stem Cell Summit is being held in West Palm Beach, Florida on December 3-5 with webcasted presentations to begin on December 3 at 8 am. Webcast Link
News For LLY;PFE;ACTC;CYTX;STEM;ATHX;LH;OVSC;NBS;PSTI;FLDM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
October 28, 2014
07:01 EDTPFEPfizer reports Q3 adjusted EPS 57c, consensus 55c
Subscribe for More Information
06:57 EDTLHLabCorp sees FY14 revenue growth 3%, consensus $5.93B
Subscribe for More Information
06:49 EDTLHLabCorp sees FY14 adjusted EPS $6.70-$6.80, consensus $6.73
Subscribe for More Information
06:48 EDTLHLabCorp reports Q3 adjusted EPS $1.80, consensus $1.75
Subscribe for More Information
October 27, 2014
19:48 EDTLLYEli Lilly responds to ruling in Takeda case
Eli Lilly (LLY) issued the following statement in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals (TKPYY) be reduced. The judge reduced the punitive damages from $3B for Lilly and $6B for Takeda to $9.2M for Lilly and $27.6M for Takeda. Plaintiffs also were awarded $1.27M in compensatory damages. The allocation of liability was 75% Takeda, 25% Lilly. "While we have empathy for the plaintiff, we believe the evidence did not support his claims," said Mike Harrington, senior VP and general counsel, Lilly. "We will continue working vigorously to overturn the verdict."
18:45 EDTLLYTakeda Pharmaceutical Co. Ltd. reponds to ruling in diabetes drug case
Subscribe for More Information
17:31 EDTLLYEli Lilly, Takeda have Actos award cut to $36.8M from $9B, Bloomberg reports
Subscribe for More Information
16:36 EDTPFEOn The Fly: Closing Wrap
Subscribe for More Information
15:36 EDTPFE, LHNotable companies reporting before tomorrow's open
Subscribe for More Information
15:18 EDTPFEEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
12:46 EDTPFEPfizer October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
08:15 EDTPFEPain Therapeutics to regain full rights to REMOXY
Subscribe for More Information
08:08 EDTPFEDURECT reports Pfizer to discontinue agreement with Pain Therapeutics
DURECT (DRRX) reported today that Pfizer (PFE) announced that it has notified Pain Therapeutics (PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics. As a result, Pain Therapeutics has the rights to develop and commercialize REMOXY on its own or with an alternative licensee. Pain Therapeutics had the rights to develop and commercialize this product candidate under a license from DURECT.
08:02 EDTPFEPfizer to discontinue agreement on REMOXY ER capsules CII
Pfizer Inc. (PFE) has notified Pain Therapeutics, Inc. (PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc. Pfizer has concluded an internal review of the top-line results of five recently completed clinical studies required to address the Complete Response Letter received in June 2011 from the U.S. Food and Drug Administration (FDA). Pfizer and Pain Therapeutics, Inc. will work together for an orderly transition of REMOXY to Pain Therapeutics, Inc. Pfizer will continue ongoing activities under the agreement for the next six months until the scheduled termination date. Pfizer supports the appropriate use of opioid pain medications, and believes that abuse-deterrent products are important to help address the growing public health problem of opioid abuse in the U.S.
07:22 EDTPFEAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
07:20 EDTSTEMAmerican Association of Blood Banks to hold annual meeting
Subscribe for More Information
06:28 EDTLLYVirbac acquires veterinary assets from Eli Lilly in U.S.
Virbac announces that it has entered into an agreement with Eli Lilly (LLY) to acquire "major" U.S. veterinary products currently marketed by Novartis (NVS) Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commissionís review of Eli Lillyís pending acquisition of Novartis Animal Health worldwide. Under the terms of this agreement, Virbac would acquire a combination of titles and rights for the U.S. on trademarks, marketing authorizations, patents, know-how, customer lists and other assets, related to two parasiticides for dogs including Sentinel Flavor Tabs and Sentinel Spectrum, currently marketed in the U.S. by Novartis Animal Health. In the U.S., Sentinel Flavor tabs and Sentinel Spectrum are expected to reach total revenues of approximately $90M-$100M in 2014. Adding these brands and commercial franchise to the current Virbac portfolio of products offered to veterinary clinics and pet owners in the U.S. will strengthen Virbacís presence and penetration in the U.S. companion animal veterinary market and leverage its growth potential. The completion of this transaction is subject to approval by the Federal Trade Commission, which Virbac expects may be received in the near future. It is also conditioned on the closing of the acquisition of Novartis Animal Health by Eli Lilly and should occur shortly thereafter.
05:26 EDTPSTIPluristem PLX-RAD cells to be studied at Case Western Reserve University
Pluristem Therapeutics announced that researchers at Case Western Reserve University will conduct a preclinical study of the Company's PLacental expanded-RAD, or PLX-RAD, cells. The study will evaluate whether PLX-RAD cells increase the success rate of human umbilical cord blood transplantation. Umbilical cord blood cells are transplanted to replace a patient's unhealthy bone marrow cells. When successful, a transplant can treat bone marrow failure, which can result from immune system disorders, genetic diseases, and leukemia treatment. When cord blood cells are administered to a patient, they travel to the bone marrow and produce healthy white and red blood cells and platelets after the patient's own abnormal cells have been eliminated. Sometimes, however, the cord blood cells fail to take hold and the transplant fails. The study at Case Western Reserve will research the feasibility of using PLX-RAD cells to help the cord blood to engraft more effectively, resulting in higher rates of successful transplantation and treatment. PLX-RAD cells are also being studied by the U.S. National Institutes of Health, NIH, for the treatment of acute radiation syndrome, or ARS, which involves bone marrow failure after exposure to high levels of radiation, as can happen after a nuclear catastrophe.
October 24, 2014
10:11 EDTACTCAdvanced Cell Technology management to meet with Jefferies
Subscribe for More Information
06:49 EDTPFEPfizer repurchase could squash AstraZeneca bid goal, Reuters says
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use